109,868 Shares in Nektar Therapeutics $NKTR Acquired by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC bought a new position in Nektar Therapeutics (NASDAQ:NKTR) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 109,868 shares of the biopharmaceutical company’s stock, valued at approximately $6,251,000.

Other large investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Nektar Therapeutics in the second quarter worth $65,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Nektar Therapeutics in the first quarter worth $68,000. Compass Wealth Management LLC bought a new stake in Nektar Therapeutics during the third quarter valued at $88,000. Finally, Bessemer Group Inc. boosted its stake in Nektar Therapeutics by 1,741.2% during the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,480 shares during the period. 75.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NKTR has been the topic of a number of research analyst reports. Oppenheimer restated an “outperform” rating and issued a $140.00 target price on shares of Nektar Therapeutics in a research note on Friday. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of Nektar Therapeutics in a research report on Monday, January 26th. Wall Street Zen lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, December 17th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.43.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the sale, the chief executive officer directly owned 75,489 shares in the company, valued at $5,510,697. This represents a 0.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Zalevsky sold 3,867 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the sale, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. This represents a 15.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 4,470 shares of company stock worth $181,955 over the last ninety days. Insiders own 5.25% of the company’s stock.

Nektar Therapeutics Stock Performance

NKTR stock opened at $73.25 on Friday. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $77.00. The firm’s fifty day moving average is $53.50 and its 200 day moving average is $53.06. The firm has a market cap of $1.49 billion, a P/E ratio of -7.18 and a beta of 1.17.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The company had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 638.32%. As a group, analysts forecast that Nektar Therapeutics will post -0.72 EPS for the current year.

Nektar Therapeutics News Roundup

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations: EPS loss of ($1.78) topped consensus and revenue of $21.8M substantially exceeded estimates; management highlighted promising clinical data and near-term plans for rezpeg Phase III studies in atopic dermatitis (timing noted for Q2 2026). Nektar Reports Fourth-Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Earnings call and analyst coverage reinforced the upside: call transcripts and press coverage flagged promising Phase 2b/clinical takeaways that appear to be driving bullish investor sentiment and volume today. Earnings Call Transcript
• Neutral Sentiment: Balance-sheet snapshot: cash and marketable securities were $245.8M at year-end (down from $269.1M a year earlier) — provides runway but still limited given development-stage spending; watch cash burn guidance and upcoming Phase III cost needs. Financial Results / Cash Position
• Negative Sentiment: Multiple law firms have filed or announced securities-fraud investigations and class action notices covering the Feb 26–Dec 15, 2025 period; several firms are soliciting lead-plaintiff motions with a May 5, 2026 deadline — litigation could lead to legal costs, management distraction and settlement risk. Rosen Law Firm Notice Pomerantz Filing

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.